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BACKGROUND: Incidence rates of cardiomyopathies, which are a 
common cause of heart failure in young people, have increased during 
the last decades. An association between body weight in adolescence and 
future cardiomyopathy among men was recently identified. Whether or 
not this holds true also for women is unknown. The aim was therefore 
to determine whether for young women being overweight or obese is 
associated with a higher risk of developing cardiomyopathy.
METHODS: This was a registry-based national prospective cohort study 
with data collected from the Swedish Medical Birth Register, 1982 
to 2014, with up to 33 years of follow-up. Included women were of 
childbearing age (18–45 years) during the initial antenatal visit in their 
first or second pregnancy (n=1 393 346). We obtained baseline data on 
body mass index (BMI), smoking, education, and previous disorders. After 
exclusions, mainly because of previous disorders, the final sample was 
composed of 1 388 571 women. Cardiomyopathy cases were identified 
by linking the Medical Birth Register to the National Patient and Cause of 
Death registers.
RESULTS: In total, we identified 1699 cases of cardiomyopathy (mean age 
at diagnosis, 46.2 [SD 9.1] years) during the follow-up with an incidence 
rate of 5.9 per 100 000 observation years. Of these, 481 were diagnosed 
with dilated cardiomyopathy, 246 had hypertrophic cardiomyopathy, 61 
had alcohol/drug-induced cardiomyopathy, and 509 had other forms. 
The lowest risk for being diagnosed with a cardiomyopathy was detected 
at a BMI of 21 kg/m2, with a gradual increase in risk with higher BMI, 
particularly for dilated cardiomyopathy, where a hazard ratio of 4.71 
(95% CI, 2.81–7.89) was found for severely obese subjects (BMI ≥35 kg/
m2), as compared with BMI 20 to <22.5.
CONCLUSIONS: Elevated BMI among young women was associated with 
an increased risk of being diagnosed with a subsequent cardiomyopathy, 
especially dilated cardiomyopathy, starting already at mildly elevated body 
weight, whereas severe obesity entailed an almost 5-fold increase in risk. 
With the increasing numbers of persons who are overweight or obese, 
higher rates of cardiomyopathy can be expected in the future, along with 
an altered disease burden related to adiposity.
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In contrast to declining incidence rates of heart fail-ure observed for elderly persons, hospitalizations for heart failure in young people are on the rise in 
Sweden and Denmark.1–3 Although cardiomyopathy is 
increasingly common as the underlying condition for 
heart failure among young persons, the most frequent 
causes in older people are coronary heart disease, hy-
pertension, and diabetes mellitus.1,3,4 Cardiomyopathies 
are a diverse group of disorders, with varying classifi-
cations proposed during the last decades. However, a 
position statement issued by the Working Group on 
Pericardial and Myocardial Diseases of the European So-
ciety of Cardiology categorized cardiomyopathies into 5 
main groups: dilated, hypertrophic, restrictive, arrhyth-
mogenic right ventricular, and unclassified.5 Discharge 
diagnoses of different types of cardiomyopathies in the 
Swedish National Hospital Register have been shown to 
be accurate in at least 85% of the cases.6
Compared with other causes of heart failure, cardio-
myopathies are rare, and risk factors for these condi-
tions are as yet scarcely explored. However, we recently 
found that higher body mass index (BMI) in adolescent 
men was associated with an increased risk for cardio-
myopathy in midlife,7 especially for dilated cardiomy-
opathy. This heightened risk appeared at levels that are 
considered high-normal (BMI 22.5 to <25 kg/m2), and 
the risk was increased more than 9-fold for the severely 
obese (BMI ≥35 kg/m2), as compared with BMI 18.5 to 
<20 kg/m2. The prevalence of overweight and obesity 
among young Swedish men and women has increased 
significantly during the last decades,8,9 which coincides 
with a rise in the number of cardiomyopathy cases in 
the Swedish population.1 In light of the association that 
we discovered recently between BMI and cardiomyopa-
thy in young men,7 we wanted to investigate whether 
this also applied to young women, in whom rates of 
cardiomyopathy have been shown to be lower than in 
men.10 Compared with the causes in men, stress-in-
duced cardiomyopathy and cardiotoxic drug exposure, 
for instance chemotherapy for breast cancer, are more 
prevalent in women, and peripartum cardiomyopathy 
is exclusive to women only.11,12 To study the long-term 
risks of developing specific types of cardiomyopathies 
(excluding cases considered to be pregnancy-related 
cardiomyopathies) across categories of BMI in young 
women, we used the Medical Birth Register, which con-
tains maternal information from 99% of the deliveries 
performed in Sweden,13 including more than 85% of all 
women in the Swedish population.14
METHODS
The raw data for our analyses are potentially identifiable. 
Access to individual-level data is possible but requires permis-
sion through the Swedish Ethical Review Authority and from 
the primary data providers: the Swedish National Board of 
Health and Welfare, and Statistics Sweden.
Study Population
The study comprised a cohort of women of childbearing age 
(18–45 years) in the Swedish Medical Birth Register who gave 
birth between January 1, 1982, and December 31, 2014, and 
who had BMI registered at the initial antenatal visit (generally 
early in the first trimester before any appreciable pregnancy-
related weight gain) during their first or second pregnancy 
(n=1 393 346). The Medical Birth Register includes data on 
deliveries in Sweden since 1973, with an estimated coverage 
of 99%. All healthcare providers submit information from the 
medical records regarding prenatal, delivery, and neonatal 
care to the register.13 Data on maternal height and weight 
have been collected for all deliveries since 1983, excluding 
1990 and 1991 (no data are available). Until 1990, early 
pregnancy weight was estimated by subtracting gestational 
weight gain from delivery weight. This was recorded with 2 
digits, which means that all women who weighed 100 kg or 
more were registered as weighing 99 kg during these years. 
From 1992 onwards, height was self-reported and weight 
was measured during the first antenatal visit (within 12 weeks 
of gestation in 90% of cases). For all the years, valid informa-
tion on height is available for 80%, and weight for 70%.13 
Visual inspection of annual body weight deciles revealed a 
larger than expected increase in body weight between 1989 
and 1992. Therefore, the weight variable for 1982 to 1989 
was adjusted by estimating annual weight gain within deciles 
from 1992 to 2003, creating an almost linear result, as pre-
viously described.15 In the present study, overweight was 
defined as BMI ≥25 kg/m2, and obesity as BMI ≥30 kg/m2. We 
also obtained data on self-reported smoking, hypertension, 
and diabetes mellitus from the register. Information regard-
ing highest maternal education level was acquired from the 
Longitudinal Integration Database for Health Insurance and 
Labor Market Studies (LISA), which includes information on 
Clinical Perspective
What Is New?
• Cardiomyopathies are increasingly common as 
underlying cause of heart failure in the young, and 
risk factors for developing these disorders are insuf-
ficiently studied, especially among women.
• The present study demonstrates that elevated body 
mass index in young women is strongly associated 
with an increased risk of subsequent cardiomyopa-
thy, starting already at mildly elevated body weight.
What Are the Clinical Implications?
• Our results emphasize the importance of prevent-
ing overweight and obesity in young people to pro-
tect from future cardiac remodeling, independently 
of ischemic heart disease.
• Along with the rising rates of overweight and obe-
sity in both women and men, a potential increase 
in cardiomyopathy cases is to be expected.
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all residents of Sweden from the age of 16 years (80% cover-
age); this was made possible by linking the registers using the 
Swedish personal identification numbers.
In the final study sample, we excluded participants with 
BMI <15 or >60 (n=1077); height <140 cm or >200 cm 
(n=370); previous pregnancy-related cardiomyopathy (n=35); 
other previous cardiomyopathy (n=172); congenital heart dis-
ease (n=3084); and previous ischemic heart disease (n=37; 
Figure I in the online-only Data Supplement).
Outcomes
The national health system in Sweden is publicly funded 
and provides specialist hospital inpatient and outpatient 
care at low cost to all residents. Diagnostic codes from visits 
or discharges are recorded in the National Patient Register, 
and information on cause-specific deaths is reported to the 
Cause of Death Register. Inpatient discharge data coverage 
increased gradually from 1970 to 1986, and is complete from 
1987, with outpatient visits registered from 2001. Primary 
care data are not included. Cardiomyopathy cases, defined 
according to the International Classification of Diseases, 8th, 
9th, and 10th Revisions, were identified through linkage to 
the National Patient and Cause of Death registers (Methods 
and Table I in the online-only Data Supplement), and cate-
gorized as (1) dilated cardiomyopathy; (2) hypertrophic car-
diomyopathy; (3) alcohol/drug-induced cardiomyopathy; (4) 
pregnancy-related cardiomyopathy; and (5) other cardiomy-
opathies (a composite of specified less-common and unspeci-
fied forms). Pregnancy-related cardiomyopathy was defined 
as being diagnosed with either new-onset heart failure or 
cardiomyopathy in the period covering 90 days before and 
180 days after delivery, or as having a peripartum cardiomy-
opathy diagnostic code (O90.3, International Classification 
of Diseases, Tenth Revision; Table I in the online-only Data 
Supplement); these were not considered as outcomes in the 
present study. Information about disorders present at baseline 
included the following diagnoses: diabetes mellitus, hyper-
tension, valvular disease, atrial fibrillation, ischemic stroke, 
hemorrhagic stroke, cancer, preeclampsia, gestational hyper-
tension, and gestational diabetes mellitus (Methods in the 
online-only Data Supplement). Cases of diabetes mellitus and 
hypertension were additionally identified by self-reported 
data from the Medical Birth Register.
Statistical Analysis
Statistical calculations were performed with R ver. 3.6.0 soft-
ware (Planting of a Tree; http://www.R-project.org). The fol-
low-up period started on the date of the first antenatal visit 
(baseline), and subjects were followed until a first cardiomy-
opathy diagnosis, including pregnancy-related cardiomyopa-
thy; death; a myocardial infarction; or the end of follow-up 
(December 31, 2014), whichever occurred first. Women with 
a pregnancy-related cardiomyopathy were censored at the 
date of diagnosis and were not included as events, because 
the risk for this condition is present exclusively around preg-
nancy, which constitutes a small fraction of the follow-up 
period. Women with a myocardial infarction before a car-
diomyopathy diagnosis were considered as having heart fail-
ure of ischemic origin and were therefore censored at the 
time of the infarction, and excluded from all analyses. A 
sensitivity analysis was performed with the Fine-Gray method 
to study competing risk, in which death was treated as a 
competing event and fatal cardiomyopathies were coded as 
cardiomyopathy events rather than deaths. Incidence rates 
and corresponding 95% CIs were calculated using Poisson 
regression. Cox proportional hazards models were used to 
estimate cause-specific hazard ratios (HR) with 95% CI, to 
assess the influence of BMI on cardiomyopathy. BMI (kg/m2) 
was categorized into 8 groups (15 to <18.5, 18.5 to <20, 
20 to <22.5, 22.5 to <25, 25 to <27.5, 27.5 to <30, 30 
to <35, 35 to <60), of which BMI 20 to <22.5 was set as 
the reference. Education was categorized into 3 groups (<9 
years, 9–12 years, >12 years of studies). The assumptions of 
proportional hazards for the regression models were exam-
ined using tests based on weighted residuals.16 Smoking and 
education did not fulfill the assumptions; hence, we strati-
fied the model for these variables. Model 1 was adjusted for 
age, year of pregnancy, and parity. Model 2 was additionally 
adjusted for baseline disorders (diabetes mellitus, hyperten-
sion, valvular disease, atrial fibrillation, ischemic stroke, hem-
orrhagic stroke, and cancer). Model 3 was further adjusted 
for smoking and education. Spline plots were generated 
based on Model 3, with BMI as a restricted cubic spline with 
degree 3 and 4 knots placed at 5% (18.9), 35% (21.7), 65% 
(24.2), and 95% (31.6). BMI values between 15 and 40 were 
plotted against the reference (BMI 21).
The study was approved by the Regional Ethical Review 
Board in Gothenburg (Dnr. 103–15).
RESULTS
Study Population and Follow-Up
The final study sample after exclusions contained 1 388 
571 women (mean age, 27.9, SD 4.9 years) with a mean 
BMI of 23.7 (SD 4.0) kg/m2. Of these, 69.1% were of 
normal weight (BMI 18.5 to <25 kg/m2), 20.1% were 
overweight (BMI 25 to <30 kg/m2), 5.6% were obese 
(BMI 30 to <35 kg/m2), and 1.9% were severely obese 
(BMI ≥35 kg/m2). Women with a first-time pregnancy 
represented 78.4% (n=1 088 420) of the study popula-
tion. Approximately 15% were smokers at the initial 
antenatal visit, with higher percentages of smokers 
among the leanest and the obese subjects. Concomi-
tant or preexisting disorders were, overall, very few in 
this young population, with diabetes mellitus (0.59%, 
n= 8205) and hypertension (0.41%, n= 5628) the most 
frequent, and rising with increasing BMI. Preeclampsia, 
gestational hypertension, and gestational diabetes mel-
litus at the index pregnancy were also more common 
with elevated BMI. The highest proportion of women 
with more than 12 years of studies was seen within the 
midrange BMI categories (Table 1).
During the up to 33 years of follow-up (median, 16 
years; interquartile interval 7–23 years), 1699 women 
(0.1% of the study population) were diagnosed with a 
cardiomyopathy at a mean age of 46.2 (SD 9.1) years (5.9 
per 100 000 observation years; Table 2). Of these, 481 
(28.3%) were diagnosed with a dilated cardiomyopathy 
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(2.2 per 100,000 observation years), 246 (14.5%) with 
a hypertrophic cardiomyopathy (1.1 per 100,000 obser-
vation years), 61 (3.6%) with an alcohol/drug-induced 
cardiomyopathy (0.3 per 100,000 observation years), 
and 509 (30.0%) with other cardiomyopathies (2.3 per 
100,000 observation years; Table  2). This last group 
consisted of 438 unspecified cardiomyopathies and 71 
specified, less common forms (Table I in the online-only 
Data Supplement). Of the 1699 cardiomyopathy cases, 
374 (22.0%) were pregnancy-related cardiomyopathies 
that occurred at the index or any future pregnancy 
(14.6 and 14.1 per 100 000 pregnancies, respectively), 
and these were censored at the date of diagnosis.
Risk for Cardiomyopathy
The lowest risk for developing a cardiomyopathy di-
agnosis was found at a baseline BMI of 21 kg/m2 
(Figure). At higher BMI values, the risk of cardiomy-
opathy rose incrementally, particularly in the case of 
dilated cardiomyopathy. The highest incidence rate for 
dilated cardiomyopathy was seen among the severely 
obese (5.8 per 100 000 observation years), at a mean 
age at diagnosis of 42.8 years (Table 2). At BMI 25 to 
<27.5 kg/m2, the HR for dilated cardiomyopathy was 
1.55 (95% CI, 1.14–2.11), as compared with BMI 20 
to <22.5, when adjusted for age, year, parity, baseline 
disorders, smoking, and education. The adjusted HR 
Table 1. Baseline Characteristics of the Study Population by BMI Category
All
BMI 15 to 
<18.5
BMI 18.5 to 
<20
BMI 20 to 
<22.5
BMI 22.5 to 
<25
BMI 25 to 
<27.5
BMI 27.5 to 
<30
BMI 30 to 
<35
BMI 35 to 
<60
Women, n (%) 1 388 571 (100) 46 212 (3.3) 140 892 (10.2) 451 365 (32.5) 366 617 (26.4) 186 306 (13.4) 92 175 (6.6) 78 384 (5.6) 26 620 (1.9)
First pregnancy, 
n (%)
1 088 420 (78.4) 36 123 (78.2) 110 277 (78.3) 354 368 (78.5) 287 757 (78.5) 145 492 (78.1) 71 822 (77.9) 61 193 (78.1) 21 388 (80.4)
Age, y (SD) 27.9 (4.9) 26.3 (4.8) 27.2 (4.8) 27.9 (4.8) 28.2 (4.9) 28.2 (5.1) 28.1 (5.2) 28.0 (5.2) 28.2 (5.2)
Height, cm (SD) 166 (6.3) 166 (6.5) 166 (6.2) 167 (6.1) 166 (6.3) 166 (6.4) 166 (6.4) 166 (6.2) 166 (6.4)
Weight, kg (SD) 65.5 (12.0) 49.0 (4.4) 53.8 (4.2) 59.2 (4.7) 65.4 (5.3) 72.2 (5.9) 79.0 (6.4) 88.0 (7.5) 105.6 (12.2)
BMI, kg/m2 (SD) 23.7 (4.0) 17.7 (0.7) 19.4 (0.4) 21.3 (0.7) 23.7 (0.7) 26.1 (0.7) 28.6 (0.7) 31.9 (1.4) 38.4 (3.2)
Smoking,* n (%) 201 592 (14.5) 9312 (20.2) 23 297 (16.5) 63 469 (14.1) 48 984 (13.4) 25 713 (13.8) 13 659 (14.8) 12 791 (16.3) 4367 (16.4)
Diabetes 
mellitus,† n (%)
8205 (0.59) 86 (0.19) 339 (0.24) 1733 (0.38) 2321 (0.63) 1530 (0.82) 874 (0.95) 895 (1.14) 427 (1.60)
Hypertension,† 
n (%)
5628 (0.41) 107 (0.23) 320 (0.23) 1273 (0.28) 1282 (0.35) 860 (0.46) 601 (0.65) 799 (1.02) 386 (1.45)
Valvular disease, 
n (%)
153 (0.01) 4 (0.009) 17 (0.012) 58 (0.013) 39 (0.011) 11 (0.006) 12 (0.013) 9 (0.011) 3 (0.011)
Atrial fibrillation, 
n (%)
178 (0.01) 4 (0.009) 18 (0.013) 49 (0.011) 54 (0.015) 23 (0.012) 9 (0.010) 16 (0.020) 5 (0.019)
Ischemic stroke, 
n (%)
279 (0.02) 7 (0.02) 31 (0.02) 79 (0.02) 76 (0.02) 38 (0.02) 19 (0.02) 20 (0.03) 9 (0.03)
Hemorrhagic 
stroke, n (%)
146 (0.01) 6 (0.013) 18 (0.013) 49 (0.011) 40 (0.011) 16 (0.009) 9 (0.010) 6 (0.008) 2 (0.008)
Cancer, n (%) 3745 (0.27) 114 (0.25) 376 (0.27) 1115 (0.25) 1014 (0.28) 544 (0.29) 253 (0.27) 251 (0.32) 79 (0.29)
Chronic kidney 
disease, n (%)
868 (0.06) 29 (0.06) 77 (0.05) 277 (0.06) 216 (0.06) 101 (0.05) 69 (0.07) 73 (0.09) 26 (0.10)
Preeclampsia, 
n (%)
49 578 (3.57) 966 (2.09) 3020 (2.14) 11 225 (2.49) 12 143 (3.31) 8257 (4.43) 5247 (5.69) 5762 (7.35) 2958 (11.11)
Gestational 
hypertension, 
n (%)
14 205 (1.02) 205 (0.44) 748 (0.53) 3195 (0.71) 3433 (0.94) 2517 (1.35) 1587 (1.72) 1749 (2.23) 771 (2.90)
Gestational 
diabetes 
mellitus, n (%)
9288 (0.67) 177 (0.38) 416 (0.30) 1530 (0.34) 1765 (0.48) 1501 (0.81) 1120 (1.22) 1654 (2.11) 1125 (4.23)
Education‡
  ≤9 y, n (%) 182 640 (13.2) 9683 (21.0) 20 233 (14.4) 53 564 (11.9) 43 808 (12.0) 24 713 (13.3) 13 577 (14.7) 12 626 (16.1) 4436 (16.7)
  10–12 y, n (%) 652 757 (47.0) 21 486 (46.5) 63 726 (45.2) 202 556 (44.9) 170 025 (46.4) 90 928 (48.8) 46 877 (50.9) 42 109 (53.7) 15 050 (56.5)
  >12 y, n (%) 537 804 (38.7) 14 337 (31.0) 55 191 (39.2) 190 333 (42.2) 149 000 (40.6) 68 680 (36.9) 30 656 (33.3) 22 759 (29.0) 6848 (25.7)
BMI indicates body mass index.
*Missing values of smoking, n=34 158 (2.5%).
†Diagnoses obtained from self-reported information in the Medical Birth Register or according to diagnostic codes in the National Patient Register.
‡Missing values of education, n=15 370 (1.1%).
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at BMI ≥35 was 4.71 (95% CI, 2.81–7.89; Table  3). 
Corresponding HRs for hypertrophic cardiomyopathy 
followed a similar pattern, except in the highest BMI 
category, where there were only two cases. Alcohol/
drug-induced cardiomyopathies were rare, with result-
ing wide CIs (Table 3). For each unit of increment in 
BMI, the HR for dilated cardiomyopathy, in the fully 
adjusted model, was 1.09 (95% CI, 1.06–1.12), for hy-
pertrophic cardiomyopathy, 1.06 (95% CI, 1.01–1.10), 
for alcohol/drug-induced cardiomyopathy, 1.03 (95% 
CI, 0.95–1.13), and 1.06 (95% CI, 1.03–1.10) for 
other cardiomyopathies (Table 3). The competing risk 
analysis, in which death was treated as a competing 
event, only changed the results marginally (Table II in 
the online-only Data Supplement).
DISCUSSION
In this nationwide cohort study of almost 1.4 mil-
lion women of childbearing age, we found that high 
BMI was associated with an increased risk of being 
diagnosed subsequently with cardiomyopathy, par-
ticularly the dilated form, independently of preexisting 
disorders, smoking, and education. The risk increased 
gradually as BMI increased across and beyond the over-
weight and obese ranges, with the highest risk seen 
for severely obese women.
Recently, we reported on a similar association be-
tween high BMI and subsequent cardiomyopathy in 
men,7 with BMI being measured in late adolescence at 
the mandatory assessment for military service that was 
undertaken by all 18-y-old males in Sweden. An equiva-
lent mandatory assessment of body weight for young 
Swedish women is not in place. However, the vast ma-
jority of women in Sweden (>85%) give birth at some 
point in life,14 and anthropometric variables are then 
registered in the Medical Birth Register.13 In this regis-
ter, rising rates of obesity have been documented,9 as 
is also the case in other national8 and global17 studies. 
In the current study, we found that 7.5% of the young 
women in the study population were obese, which is 
somewhat lower than in other Swedish reports that in-
cluded older age categories, and with data from the 
later time period of the present study.18,19 However, ac-
cording to a recent publication from the National Board 
of Health and Welfare in Sweden, the prevalence of 
Table 2. Event Rates per 100 000 Observation Years for Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Alcohol/Drug-Induced 
Cardiomyopathy, and Other Cardiomyopathies by BMI Category
All
BMI 15 to 
<18.5
BMI 18.5 to 
<20
BMI 20 to 
<22.5
BMI 22.5 to 
<25
BMI 25 to 
<27.5
BMI 27.5 to 
<30
BMI 30 to 
<35
BMI 35 to 
<60
Women, n (% of total) 1 388 571 
(100)
46 212 (3.3) 140 892 (10.2) 451 365 (32.5) 366 617 (26.4) 186 306 (13.4) 92 175 (6.6) 78 384 (5.6) 26 620 (1.9)
Age at cardiomyopathy 
diagnosis* (SD), y
46.2 (9.1) 44.9 (9.0) 45.4 (9.2) 47.4 (8.8) 46.2 (9.7) 46.3 (8.6) 45.3 (9.1) 45.0 (8.3) 42.9 (9.9)
Follow-up time,
median (Q1, Q3)
16 (7, 23) 18 (8, 27) 18 (8, 27) 18 (8, 26) 16 (8, 23) 14 (7, 22) 13 (6, 21) 12 (6, 20) 10 (5, 16)
Dilated cardiomyopathy
  Events, n (%) 481 (0.03) 22 (0.05) 55 (0.04) 131 (0.03) 112 (0.03) 66 (0.04) 39 (0.04) 39 (0.05) 17 (0.06)
  Cases per 100 000 
observation y  
(95% CI)
2.2 (2.0–2.4) 2.7 (1.7–4.1) 2.2 (1.7–2.9) 1.7 (1.4–2.0) 1.9 (1.6–2.3) 2.4 (1.8–3.0) 3.0 (2.1–4.1) 3.7 (2.6–5.0) 5.8 (3.4–9.2)
Hypertrophic cardiomyopathy
  Events, n (%) 246 (0.02) 3 (0.006) 24 (0.017) 69 (0.015) 61 (0.017) 41 (0.022) 23 (0.025) 23 (0.029) 2 (0.008)
  Cases per 100 000 
observation y  
(95% CI)
1.1 (1.0–1.3) 0.4 (0.08–1.1) 1.0 (0.6–1.4) 0.9 (0.7–1.1) 1.0 (0.8–1.3) 1.5 (1.1–2.0) 1.8 (1.1–2.7) 2.2 (1.4–3.3) 0.7 (0.08–2.5)
Alcohol/drug-induced cardiomyopathy
  Events, n (%) 61 (0.004) 3 (0.006) 6 (0.004) 12 (0.003) 23 (0.006) 5 (0.003) 4 (0.004) 7 (0.009) 1 (0.004)
  Cases per 100 000 
observation y  
(95% CI)
0.3 (0.2–0.4) 0.4 (0.08–1.1) 0.2 (0.09–0.5) 0.2 (0.08–0.3) 0.4 (0.3–0.6) 0.2 (0.06–0.4) 0.3 (0.08–0.8) 0.7 (0.3–1.4) 0.3 (0.01–1.9)
Other cardiomyopathies
  Events, n (%) 509 (0.04) 15 (0.03) 56 (0.04) 176 (0.04) 112 (0.03) 67 (0.04) 37 (0.04) 33 (0.04) 13 (0.05)
  Cases per 100 000 
observation y  
(95% CI)
2.3 (2.1–2.5) 1.9 (1.0–3.1) 2.3 (1.7–2.9) 2.3 (2.0–2.6) 1.9 (1.6–2.3) 2.4 (1.9–3.1) 2.9 (2.0–3.9) 3.1 (2.1–4.4) 4.4 (2.4–7.5)
BMI indicates body mass index; Q1, quartile 1; and Q3, quartile 3.
*Pregnancy-related cardiomyopathy not included.
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maternal obesity continues to increase and was as high 
as 15.1% in 2017.20
An association between obesity in middle-aged 
women and heart failure has previously been shown 
in a report based on the Prospective Population Study 
of Women and H70 Studies in Sweden.21 In the current 
study, we investigated a more specific epidemiological 
association, considering the different forms of cardio-
myopathy. Although it is true that heart failure and 
cardiomyopathy overlap, they are not interchangeable, 
which becomes even more clear when the term “car-
diomyopathy” is used correctly.5 The lack of previous 
knowledge about the relationship between adiposity in 
young women and different types of cardiomyopathy 
highlights the novelty of these findings. Apart from our 
study of men,7 we have found only 1 previous study 
relevant to this topic, based on a cohort of 2.3 million 
Israeli adolescents,22 demonstrating a gradual increase 
in risk of cardiomyopathy-related death with increas-
ing BMI. That study, however, identified only 121 car-
diomyopathy deaths and was not sufficiently powered 
to investigate specific forms of cardiomyopathy or the 
association with severe obesity, which constitutes an in-
creasing proportion of overweight persons.8
Compared with our results for adolescent men,7 the 
present incidence rates of dilated and hypertrophic car-
diomyopathies for females were lower, in accordance 
with previous findings,23–25 showing a prevalence of 
idiopathic dilated cardiomyopathy between 1:1.9 and 
1:4.3 for the female-to-male ratios, whereas hypertro-
phic cardiomyopathy has been somewhat more equally 
distributed between the sexes.23,24 Reports on alcoholic 
cardiomyopathy have been inconclusive.26,27 However, 
we noted a lower incidence of alcohol/drug-induced 
cardiomyopathy among women than in our study of 
men.7 Further, we found a slightly higher BMI threshold 
for women, who were on average a decade older than 
the men. Notably, men are known to have higher risks 
for diabetes mellitus,28 and mortality29 for a given BMI 
than women, so our results appear to fit with the slight 
sex differences observed for the association between 
adiposity and adverse health outcomes. In the current 
study, the risk for dilated cardiomyopathy, in particular, 
was associated with higher BMI, a pattern similar to 
Figure. Association between body mass index (BMI) in young women and risk for subsequent cardiomyopathy.
The model is adjusted for age, year, parity, comorbidities at baseline, smoking, and level of education (n=1 339 527). BMI is restricted to the range of 15 to 40, and 
modeled as a restricted cubic spline with knots at 5%, 35%, 65%, and 95% (i.e., 18.9, 21.7, 24.2, and 31.6, respectively), with a BMI of 21 as reference.
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Table 3. Hazard Ratios (95% CIs) for Cases With Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Alcohol/
Drug-Induced Cardiomyopathy, and Other Cardiomyopathies by BMI Category
BMI category
Hazard Ratio (95% CI)
Model I* Model II† Model III‡
Dilated cardiomyopathy
 Events/population 481/1 388 368 481/1 388 368 457/1 339 527
 15 to <18.5 1.69 (1.08–2.66) 1.69 (1.08–2.66) 1.65 (1.03–2.62)
 18.5 to <20 1.33 (0.97–1.82) 1.33 (0.97–1.82) 1.33 (0.96–1.84)
 20 to <22.5 1 (reference) 1 (reference) 1 (reference)
 22.5 to <25 1.18 (0.92–1.52) 1.18 (0.92–1.52) 1.20 (0.93–1.56)
 25 to <27.5 1.59 (1.18–2.14) 1.58 (1.18–2.13) 1.55 (1.14–2.11)
 27.5 to <30 2.08 (1.45–2.98) 2.07 (1.45–2.97) 1.98 (1.37–2.86)
 30 to <35 2.63 (1.83–3.76) 2.61 (1.82–3.73) 2.43 (1.67–3.52)
 35 to <60 5.07 (3.04–8.45) 5.02 (3.01–8.38) 4.71 (2.81–7.89)
 Per 1-unit increase in BMI (95% CI)§ 1.10 (1.07–1.13) 1.09 (1.06–1.13) 1.09 (1.06–1.12)
Hypertrophic cardiomyopathy
 Events/population 246/1 388 368 246/1 388 368 233/1 339 527
 15 to <18.5 0.45 (0.14–1.43) 0.45 (0.14–1.44) 0.47 (0.15–1.50)
 18.5 to <20 1.12 (0.70–1.78) 1.12 (0.70–1.78) 1.14 (0.71–1.83)
 20 to <22.5 1 (reference) 1 (reference) 1 (reference)
 22.5 to <25 1.20 (0.85–1.70) 1.19 (0.84–1.68) 1.17 (0.82–1.67)
 25 to <27.5 1.81 (1.22–2.66) 1.77 (1.20–2.61) 1.70 (1.14–2.54)
 27.5 to <30 2.21 (1.38–3.56) 2.14 (1.33–3.45) 2.11 (1.30–3.44)
 30 to <35 2.77 (1.73–4.46) 2.60 (1.62–4.19) 2.65 (1.64–4.29)
 35 to <60 0.97 (0.24–3.99) 0.88 (0.21–3.62) 0.89 (0.22–3.67)
 Per 1-unit increase in BMI (95% CI)§ 1.06 (1.02–1.11) 1.05 (1.01–1.10) 1.06 (1.01–1.10)
Alcohol/Drug-induced cardiomyopathy
 Events/population 61/1 388 368 61/1 388 368 56/1 339 527
 15 to <18.5 2.32 (0.65–8.25) 2.34 (0.73–7.46) 2.31 (0.63–8.42)
 18.5 to <20 1.53 (0.57–4.07) 1.53 (0.66–3.56) 1.68 (0.61–4.63)
 20 to <22.5 1 (reference) 1 (reference) 1 (reference)
 22.5 to <25 2.67 (1.33–5.36) 2.65 (1.58–4.44) 2.84 (1.33–6.03)
 25 to <27.5 1.31 (0.46–3.73) 1.30 (0.52–3.25) 1.43 (0.49–4.20)
 27.5 to <30 2.31 (0.74–7.17) 2.28 (0.83–6.29) 1.78 (0.49–6.50)
 30 to <35 5.06 (1.98–12.9) 4.92 (2.24–10.8) 4.94 (1.87–13.1)
 35 to <60 3.32 (0.43–25.8) 3.27 (0.45–23.7) 2.96 (0.37–23.5)
 Per 1-unit increase in BMI (95% CI)§ 1.04 (0.96–1.14) 1.04 (0.96–1.14) 1.03 (0.95–1.13)
Other cardiomyopathies
 Events/population 509/1 388 368 509/1 388 368 490/1 339 527
 15 to <18.5 0.87 (0.51–1.47) 0.87 (0.51–1.47) 0.75 (0.43–1.32)
 18.5 to <20 1.02 (0.75–1.38) 1.02 (0.75–1.38) 0.93 (0.68–1.27)
 20 to <22.5 1 (reference) 1 (reference) 1 (reference)
 22.5 to <25 0.85 (0.67–1.07) 0.84 (0.66–1.07) 0.86 (0.67–1.09)
 25 to <27.5 1.10 (0.83–1.47) 1.09 (0.82–1.45) 1.07 (0.81–1.43)
 27.5 to <30 1.32 (0.93–1.89) 1.30 (0.91–1.86) 1.20 (0.83–1.74)
 30 to <35 1.47 (1.01–2.14) 1.43 (0.98–2.07) 1.42 (0.98–2.07)
 35 to <60 2.21 (1.25–3.90) 2.11 (1.19–3.73) 2.07 (1.17–3.66)
 Per 1-unit increase in BMI (95% CI)§ 1.07 (1.04–1.10) 1.07 (1.04–1.10) 1.06 (1.03–1.10)
BMI indicates body mass index.
*Model I adjusted for age, year, and parity. Women with pregnancy-related cardiomyopathy (n=203) were excluded at baseline.
†Model II additionally adjusted for disorders at baseline (diabetes mellitus, hypertension, valvular disease, atrial fibrillation, ischemic 
stroke, hemorrhagic stroke, and cancer). Women with pregnancy-related cardiomyopathy (n=203) were excluded at baseline.
‡Model III additionally adjusted for smoking and education. Women with pregnancy-related cardiomyopathy (n=203) were 
excluded at baseline, and 48 841 women were excluded due to missing values of smoking and/or education.
§Calculated for BMI ≥22.5 (n=749 967 for model I and II, n=725 150 for model III).
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that of men.7 Our finding of an increased risk for dilated 
cardiomyopathy at the lower end of the BMI spectrum 
must be interpreted with caution, because this group 
only comprised a small number of events. Speculatively, 
higher rates of smoking, poor nutrition status, as well as 
alcohol or substance abuse may have predisposed un-
derweight women to future cardiac disease, but in the 
absence of data, this cannot be confirmed. Although 
there were too few cases to allow solid conclusions, the 
association between BMI and hypertrophic cardiomy-
opathy followed the same trend as for dilated cardio-
myopathy, even though most cases are thought to be 
hereditary.30 This suggests that high BMI exacerbates or 
synergizes with genetic defects in cardiac function, and 
thus, probably results in earlier expression of symptoms. 
However, as genetic testing has not been routinely avail-
able on a national basis until recently, this hypothesis 
could not be investigated in the present study.
The association that we found between BMI and car-
diomyopathy may be derived from myocardial remodel-
ing in obese subjects, as shown in a report on young 
otherwise healthy women.31 This indicates an early on-
set of potentially adverse alterations in the myocardium 
that is related to obesity at a young age. Elevated body 
weight entails an increased metabolic demand that re-
quires hemodynamic changes including increased blood 
volume and cardiac output. Over time, this results in 
ventricular dilation and hypertrophy along with impaired 
cardiac function.32 Another contributing mechanism is 
the increased secretion of adipocyte-derived molecules 
that comes with excess adipose tissue, for instance, 
leptin, neprilysin, and aldosterone.33 This has been pro-
posed to promote a proinflammatory state, which may 
lead to cardiac fibrosis and microvascular abnormalities. 
Accordingly, there is a growing body of evidence sug-
gesting that systemic inflammation may play a major role 
in the pathogenesis of heart failure.34 Other postulated 
mechanisms that link adiposity to cardiac remodeling 
and dysfunction include high levels of oxidative stress, 
as well as myocardial lipotoxicity, in which intracellular 
accumulation of excess fatty acid and triglycerides leads 
to apoptosis of the cardiac myocytes.35 Taken together, 
the pathophysiology of obesity-related cardiomyopathy 
is not fully understood, but appears to involve a multi-
faceted interplay between increased hemodynamic load, 
neurohormonal dysregulation, inflammation, and lipo-
toxicity among others.
Strengths and Limitations
The present nationwide cohort study included almost 
1.4 million women for up to 33 years of follow-up. 
This enabled an analysis with adequate statistical pre-
cision, despite a relatively low rate of female cardio-
myopathy events in midlife. Almost all (99%) of the 
women who gave birth in Sweden during the study 
period, representing a large majority of Swedish wom-
en,14 were included. This indicates that the study pop-
ulation was adequately representative of women in 
Sweden. However, involuntary childlessness is known 
to be more common among obese women,36 so it is 
possible that the incidences of cardiomyopathies may 
have been underestimated.
Along with our previous results for men,7 the pres-
ent study showed that being overweight or obese is 
associated with cardiomyopathy regardless of sex. It is 
likely that our findings can be generalized to other eth-
nicities, although this needs to be confirmed in future 
studies. Furthermore, a validation study of cardiomyop-
athy diagnoses in the National Hospital Register during 
an overlapping period with this report showed a high 
diagnostic accuracy (>85%), which did not change dur-
ing the study period, with almost uniform use of echo-
cardiography in investigations of suspected cardiomy-
opathy throughout those years.6 Thus, we believe that 
most of the cardiomyopathy cases in the current study 
were accurately diagnosed.
Moreover, in the Medical Birth Register, height 
was occasionally self-reported, and as women tend 
to overestimate this measurement,37 BMI values may 
have been underestimated in some cases. We consid-
ered measured weight at the first antenatal visit, most 
of which occurred within 12 weeks of gestation,13 to 
be a satisfactory estimate of prepregnancy weight, as 
weight gain during the first trimester has been report-
ed to be negligible.38–40 Anthropometric variables other 
than BMI, such as waist circumference and waist-to-
hip ratio, were not available in the dataset, although 
we recognize central fat accumulation appears more 
strongly linked to adverse metabolic outcomes in 
women than in men.41 Further, diabetes mellitus and 
hypertension were probably underestimated in this 
study population because of lack of primary care data. 
Another limitation was the inaccessibility of informa-
tion on body weight and other potential risk factors 
during the 33-y follow-up. Although repeated indi-
vidual measurements of BMI could be obtained from 
women with subsequent pregnancies, these would 
mostly be confined to a decade, which only represents 
the first years of the follow-up period. Data on BMI 
from the later part of the follow-up (closer to the car-
diomyopathy event) would still be missing. Thus, we 
believe that including repeated measurements of BMI 
in pregnant women would not meaningfully enhance 
our analyses as only minimal additional information on 
the longitudinal relationship between BMI and cardio-
myopathy risk would be provided. Even so, BMI has 
been demonstrated to be highly consistent in terms of 
tracking during life,42 and accordingly any cardiac ab-
normalities may well result from a continuing effect of 
elevated body weight. It seems unlikely that repeated 
measurements would have changed our conclusions.
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Conclusions
Higher BMI among young women was associated with 
an increased risk of being diagnosed with a subsequent 
cardiomyopathy, especially dilated cardiomyopathy, 
starting already at mildly elevated body weight, where-
as severe obesity entailed an almost 5-fold increase in 
risk. This is in line with previous findings for young men. 
If these associations are at least partially causal, with 
increasing numbers of people who are overweight or 
obese, higher rates of cardiomyopathies, along with an 
altered disease burden related to adiposity, can be ex-
pected in the future.
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